Complete publications

  1. Topical Mitomycin C Therapy for Carcinoma of the Bladder
    J Urol, 1987, Vol 128, 1164-1166
    Stricker, Grant, Holsken, Taylor
  2. Prophylactic Antibiotics for Elective TURP. Br.
    J. Urol. June 1988, Vol 61, 494-497
    Stricker, Grant
  3. Mitomycin C for Bladder Carcinoma. Long Term Follow-up
    J.Urol. 1990 (143, 34-36).
    Stricker, Grant, Hosken, Taylor
  4. The Investigation of Male Sexual Dysfunction (Review)
    Medical Journal of Australia - July 1991.
    Stricker P
  5. BCG enhances monocyte and lymphocyte mediated bladder tumour cell killing
    Br J Cancer. 1995 Apr;71(4):801-7.
    Pryor K, Goddard J, Goldstein D, Stricker P, Russell P, Golovsky D, Penny R
  6. Advances in the treatment of superficial bladder cancer: Optimising BCG Immunotherapy Case Discussions
    European Urology, Feb 1995, Supp, 32-33.
    Stricker P
  7. Antiproliferative effects of B.C.G. and Interferon A2B on human bladder cancer cells invitro
    Cancer Immunol Immunother. 1995 Nov;41(5):309-16.
    Pryor K, Stricker P, Russell P, Golovsky D, Penny R
  8. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer
    Urology - 1996 Dec;48(6):957-61; discussion 961-2
    Stricker P, Pryor K, et.al
  9. Prostate Cancer: Don't be too casual
    Med J Aust. 1996 Mar 4;164(5):319-20.
    Stricker P
  10. Risks of self -injection therapy for impotence
    M.J.A. letter 1996; 165: 117-118.
    Millard R J , Stricker P, Lynch W et.al
  11. Management of Localised Prostate Cancer: state of the art
    Med J Aust 1998; 169 (1): 11-12.
    Frydenberg M, Duchesne G, Stricker P
  12. Prostate Cancer Diagnosis and Management
    Lancet 1997; 349: 1681–87
    Frydenberg M, Stricker P, Kaye KW
  13. Growth Factor Involvement in Progression of Prostate Cancer
    Clinical Chemistry 44:4 705–723 (1998)
    Russell P, Bennett S
  14. Elevated levels of Peritumoral chondroitin Sulfate are Predictive of poor prognosis in patients treated by Radical Prostatectomy for early stage prostate cancer Cancer Res 1999, May 15, 59 (10.; 2324-8)
    Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland R L, Stricker P, Grygiel J J, Sutherland R L, Marshall VR, Tilley WD, Horsfall DJ.
  15. Lower urinary tract symptoms in the male. Benign prostatic hyperplasia
    MedicineToday. February 2000: 20-33
    Kooner R and Stricker P.
  16. Prognostic significance of P53: Nuclear accumulation is localised prostate cancer treated with radical prostatectomy
    Cancer Res, March 15, 2000.
    Quinn D I, Lee C S, Head D R, Golovsky D, Brenner P ., Delprado W, Stricker P, Grygiel JJ, Sutherland R L
  17. Altered expression of Androgen receptor in the malignant epithelium and adjacent stroma is association with early relapse in prostate cancer
    Cancer Res 61:423-7. (2001).
    Henshall S.M., Quinn D I, Lee C S, Head D R, Golovsky D, Brenner P.C., Deprado W., Stricker P.D., Grygiel J J, Sutherland R.
  18. Over Expression of the cell cycle inhibitor p161NK4A in high grade intraepithelial neoplasia predicts early relapse in prostate cancer patients
    Clin Cancer Res. 2001 Mar;7(3):544-50.
    Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky D, Brenner PC, Delprado W, Stricker P, Grygiel JJ, Sutherland RL.
  19. Frequent loss of oestrogen Receptor - B expression in prostate cancer and its association with outcome.
    Cancer Res 61:5331-5. (2001).
    A, Sutherland RL , Horvath L., Henshall S.M., Lee C S, Head D R, Quinn D I, Makela S., Delprado W., Golovsky D, Brenner P.C., O'Neill G., Kooner R, Stricker P, Grygiel ., Gustafsson J
  20. Prostate Cancer Part 1. Issues in Screening and Diagnosis
    Medicine Today. July 2001: 20-31
    Stricker P
  21. Prostate Cancer Part 2 - Options in Treatment
    Medicine Today. August 2001: 30-38
    Stricker P
  22. Implications for staging systems and predictive models.
    J. Clin Oncol. 19:3692-705. (2001)
    Quinn D., Henshall S.M., Haynes A.M., Brenner P.C., Kooner R., Golovsky D, Matthews J., O'Neill G.F., Turner J.J., Delprado W., Finlayson J.F., Sutherland R.L., Grygiel J J, Stricker P.D., Prognostic significance of pathological features in localised prostate cancer treated with radical prostatectomy.
  23. A study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localised prostate cancer.
    J.Clin. Oncol 20: 951-956. (2002).
    Graefen M, Karakiewics PI, Cagiannos I, Klein E, Kupelian P, Quinn DI, Henshall SM, Grygiel JJ, Sutherland R L, Stricker P, deKemion J, Cangiano T, Scherder F H, Wildhagen M F, Scardino PT, Kattan MW
  24. International validation of a pre-operative nomogram prostate cancer recurrence after radical prostatectomy
    J. Clin Oncol: 20: 3206- 3212 (2002)
    M., Grygiel J J, Sutherland R.L., Stricker P.D., Klein E., Kupelian P., Skinner D.G., Lieskovsky G., Bochner B., Huland H., Hammerer P.G., Hease A., Erbersdobler A., Eastham J. A., de Kernion J., Cangiano T., Schroder F.H., Wildhagen M.F., van der Kwast T., Scardino P T, Kattan M W, Graefen Karakiewicz P I, Cagiannos I, Quinn D I, Henshall S
  25. Treatment of localised prostate cancer using a combination of HDR Iridium 192, Brachytherapy and EBRT.
    Australasian Radiology. 2003 47:152-160
    Stevens M, Stricker P, Saalfeld J et.al
  26. Prognostic significance of pre-operative factors in localised prostate cancer treated with radical prostatectomy: importance of percentage of biopsies that contain cancer and presence of biopsy perineural invasion
    Cancer April 2003 97:1884-1893
    Quinn DI, Henshall SM, Haynes AM, Winoto LFX, Brenner PC, Kooner R, Golovsky D, O'Neill GF, Turner J J, Delprado W, Finalyson JF, Grygiel JJ, Sutherland R L, Stricker P.
  27. ZNT4 in the progression of prostate cancer.
    Oncogene 22, 6005-6012 (2003).
    Henshall SM, Afar DEH, Rasiah KK, Horvath LG, Gish K, Head DR, Caras I, Kensh JG, Ramakrishnan V, Quinn DI, Turner J J, Delprado W, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker P, Grygiel JJ, Mack D, Sutherland R L.
  28. A Pre-operative nomogram identifying prostate cancer patients with decreased risk of positive pelvic lymph nodes.
    Journal of Urology.2003 170:1798-1803
    Cagiannos I, Karakiewicz PI, Eastman, Ohiri, Rabbani, Juland, Kupelian, Klein, Quinn DI, Henshall SM, Grygiel JJ, Sutherland R L, Stricker P, Morash, Scardino PT.
  29. Survival analysis of genome-wide gene profiles of prostate cancers identifies new prognostic targets of disease relapse.
    Cancer Res 2003. 63:4196-4203
    Henshall SM, Afar DEH, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench J, Stricker P, Grygiel JJ, Ghandour G, Mack D, Sutherland R L.
  30. The prognostic significance of Gleason pattern in patients with Gleason 7 prostate cancer.
    Cancer 2003. Dec 15; Volume 98/Number 12, 2560-5
    K. Rasiah, Phillip D. Stricker, Haynes A, Warick Delprado, Jennifer J Turner, Golovsky D, Phillip C Brenner, Gordon O'Neill, Kooner R, John J Grygiel, Robert L Sutherland, Susan M Henshall .
  31. Clinical Cancer Research: January 15 2004, Vol 10, 615-625
    Horvath LG, Brenner PC, O'Neill GF, Kooner R, Stricker P, Grygiel JJ and Sutherland R L Membraneous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC-3 cellular proliferation in vitro.
  32. Radical Prostatectomy: A personal series of 700 cases over 14 years: Evolution in technique.
    ANZ J. Surg. 2004; 74: A1-A8
    P.Stricker, J Matthews and Haynes A.
  33. Determining predictors of insignificant cancer in Gleason sum 6 prostate cancer.
    ANZ J. Surg. 2004;74: A1-A8
    M.Hoch, Rasiah K, H Haxhimolla, Haynes A, and P Stricker.
  34. Solitary positive apical margin a treatment dilemma.
    ANZ J. Surg. 2004;74: A1-A8
    ZH Haxhimolla, SP David, Rasiah K, Haynes A, K Luo, D Golovsky and P Stricker.
  35. Identification of novel markers of prognosis in high grade intraepithelial neoplasia and early prostate cancer.
    ANZ J. Surg. 2004;74: A1-A8
    K Rasiah K, SM Henshall, JG Kench, LG Horvarth, D Golovsky, PC Brenner, R Kooner, G O'Neill, J Turner, W Delprado, CS Lee, PD Stricker and RL Sutherland.
  36. Is year of radical prostatectomy a predictor of outcome in prostate cancer.
    J Urol 171: 692-696. (2004).
    Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohiro M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer PG, Erbersdobler A, Schroeder F, Wildhagen MF, Quinn DI, Henshall SM, Grygiel JJ, Sutherland R L, Stricker P, Morash CG, Scardino PT and Kattan MW.
  37. Loss of BMP2, SMAD8 and SMAD4 expression in prostate cancer progression
    The Prostate 59: 234- 242 (2004).
    Horvath LG., Henshall SM, Kench.JG, Turner.JJ, Golovsky D, Brenner PC, O'Neill G, Kooner R, Stricker P, Grygiel JJ, Sutherland R L.
  38. Membraneous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC-3 cellular proliferation in vitro
    Clinical Cancer Research: Vol 10, 615-625, January 15, 2004.
    Horvath LG, Brenner PC, O'Neill GF, Kooner R, Stricker P, Grygiel JJ and Sutherland R L
  39. Preclinical Validation of anti-TMEFF2- auristatin E-conjugated antibodies in the treatment of prostate cancer.
    Molecular Cancer Therapeutics 2004:3 (8. August 2004)
    Daniel Afar, Vinay Bhasker, Stricker P et al.
  40. Localised Prostate Cancer - Questions Patients Ask
    MedicineToday. September 2004, Volume 5, Number 9:18-32
    Adshead J, Stricker P.
  41. Efficacy and safety of Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy
    European Urology Supplements 3 (2004. No 2, pg 33).
    Pierre Teillac, Stricker P et al.
  42. Lower levels of nuclear B-catenin predict for a poorer prognosis in localized prostate cancer.
    Int J Cancer: 113, 415-422 (2005).
    Horvath LG, Henshall SM, Lee C-S, Kench JG, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker P, Grygiel JJ and Sutherland R L
  43. Stratification by outcomes affecting response to Viagra in the treatment of erectile dysfunction during the first 6 months following radical prostatectomy .
    European Urology Supplements 3 (2004. No 2, pg 32).
    Francesco Montorsi, Stricker P et al.
  44. The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer Outcomes
    Cancer Res 2005; 65(6. March 15, 2005).
    Asne Bauskin, David Brown, Simon Junankar, Kris Rasiah, Sarah Eggleton, Mark Hunter, Tao Liu, Dave Smith, Tamara Kuffner, Greg Pankhurst, Heiko Johnen, Pamela Russell, Wade Barret, Stricker P, John Grygiel, James Kench, Henshal Sl, Robert Sutherland, Samuel Breit.
  45. Cross sectional analysis of sexual function after prostate brachytherapy
    Urology 66377-381. (2005).
    Finney G, Haynes A-M, Cross P, Brenner PC, Stricker P.
  46. Assessing and managing benign prostatic hyperplasia.
    Medicine Today September 2005, Vol. 6, Number 9:12 22.
    Petr Macek, Dinesh Patel and Stricker P.
  47. Prognostic Impact of Positive Surgical Margins in Surgically Treated Prostate Cancer: Multi-institutional Assessment of 5831 Patients .
    Urology. 2005 Dec;66 (6:1245-50).
    Karakiewicz PI, Eastham JA, Graefen M, Cagiannos I, Stricker P, Klein E, Cangiano T, Schroder FH, Scardino PT, Kattan MW.
  48. Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 Expression are early events in prostate cancer development and are associated with poor prognosis.
    Cancer Epidemiol Biomarkers Prev 2006;15 (4. April 2006).
    Soon Lee, David Brown, Samuel Breit, John Grygiel, Horvath L, Stricker P, Robert Sutherland, Henshal Sl. Kris Rasiah, James Kench, Margaret Gardiner-Garden, Andrew Biankin, Golovsky D, Phillip Brenner, Kooner R, Gordon O'Neill, Jennifer Turner, Warick Delprado, C.
  49. Outcomes of radical prostatectomies and HDR brachytherapy in patients with intermediate and high risk prostate cancer. 2006 BJU International. Abstracts.
    P Macek, P Stricker, M Stevens, Jagavka Rr, V Chalasani, Haynes A, J Matthews, P Brenner, D Golovsky, R Kooner and G O'Neill.
  50. Treatment of localised prostate cancer using a combination of high dose-rate Ir-192 brachytherapy (HDRB) and external beam radiation therapy (EBRT): a 7 year experience
    BJU International. Abstracts (2006)
    M Stevens, P Stricker, J Saalfeld, P Brenner and R Kooner.
  51. Zinc-alpha2-glycoprotein Expression as a Predictor of Metastatic Prostate Cancer Following Radical Prostatectomy
    Journal of the National Cancer Institute, Vol 98, No.19, October 4 2006.
    Henshal Sl, Horvath L, David Quinn, Sarah Eggleton, John Grygiel, Stricker P, Andrew Biankin, James Kench, Robert Sutherland.
  52. Saw palmetto and lower urinary tract symptoms in men
    MedicineToday. August 2007, Vol. 8, Number 8: 71-72
    Chabert C, Maianski Z, Stricker P
  53. Approaches to Nerve Sparing Retrograde Athermal Technique
    Journal of Robotic Surgery 2008 (2) 105-133
    Stricker P
  54. Ethical Introduction of Robotic Radical Prostatectomy Surgery for an Experienced Open Surgeon
    Journal of Robotic 2008 (2) 105-133
    Stricker P
  55. Immunohistochemical Level of Unsulfated Chondroitin Disaccharides in the Cancer Stroma is an Independent Predictor of Prostate Cancer Relapse
    Cancer Epidemiol Biomarkers Prev 2008;17(9). September 2008 pg2488-97
    Sakko AJ, Butler MS, Byers S, Reinboth BJ, Stahl J, Kench JG, Horvath LG, Sutherland RL, Stricker P, Henshall SM, Marshall VR, Tilley WD, Horsfall DJ, Ricciardelli C
  56. Randomised, Double-Blind, Placebo-Controlled Study of Postoperative Nightly SildenafilCitrate for the Prevention of Erectile Dysfunction after Bilateral Nerve-Sparing Radical Prostatectomy.
    Int J Impot Res. 2008 Sep-Oct; 20(5): 479-86. Epub 2008 Jul 24.
    Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegal R, Montorsi F, Giuliano F, Brock G; Study Group (Stricker P).
  57. Androgen Regulation of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) in Prostate Cancer.
    Prostate. 2008 Sep 15; 68 (13): 1421-9
    Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker P, Grygiel JG, Sutherland R L, Henshall SM, Allen JD, Horvath LG.
  58. HSD17B4 Overexpression, an Independent Biomaker of Poor Outcome in Prostate Cancer
    Mol Cell Endocrinol. 2008 Nov 28.
    Rasiah KK, Gardiner-Garden M, Padilla EJ, Moller G, Kench JG, Alles MC, Eggleton SA, Stricker P, Adamski J, Sutherland R L, Henshall SM, Hayes VM
  59. Stage Migration in Localised Prostate Cancer has No Impact on the Post Radical Prostatectomy Kattan Nomogram
    BJU International 2010. March 105 (5) 642-7
    Ruban Thanigasalam, Krishan Rasiah, Stricker P, Brenner P, Golovsky D, Kooner R, O ’Neill G, Arul Earnest, Haynes A, Sutherland S, Henshal Sl, Horvath L.
  60. Quality of Life Three Years After Treatment for Localised Prostate Cancer: A Population-Based Study
    BMJ 2009. Nov 27, 339-b4817
    Smith DP, King MT, Egger S, Berry M, Stricker P, Cozzi P, Ward J, O ’Connell DL, Armstrong BK
  61. Treatment for Localised Prostate Cancer
    Medicine Today July 2009; 10(7): 63-66
    Charles Chabert, Stricker P
  62. Should Experienced Open Prostatic Surgeons Convert to Robotic Surgery? The Real Learning curve for One Surgeon over 3 Years
    BJU Int: 10.1111/j. 1464-410X.2009.0958x
    Doumerc N, Yuen C, Savdie R, Bayzidur Rahman M, Rasiah K, PeBenito R, Delprado W , Matthews J, Haynes A, Stricker P
  63. A Practical Guide on PSA Testing
    Medicine Today 2009; 10(11): 57-61
    Stricker P
  64. Prospective Comparative Analysis of Clinico-Pathological Outcomes Between Robotic Assisted and Open Radical Prostatectomy
    The Authors Journal Compilation. 2009 BJU International. 103, Supplement 1, 1-48. Abstract.
    P Chen, R Thanigasalam, S Henshall, Haynes A, J Matthews and P Stricker.
  65. The Clinico-Pathological Outcome of Men Undergoing Prostatectomy with PSA < 4
    The Authors Journal Compilation. 2009 BJU International. 103 Supplement 1. 1-48. Abstract.
    P Chen, R Thanigasalam, P Stricker, J Matthews, DeBenito R, Haynes A, S Henshall and Rasiah K.
  66. The Impact of Nerve Sparing Surgical Margin Status and Oncological Outcome in Radical Prostatectomy
    The Authors Journal Compilation. 2010 BJU International. 105 Supplement 1. 1-38. Abstract.
    B Moore, DeBenito R, Haynes A, P Stricker.
  67. High-Risk Prostate Cancer: Comparison of 10 Year Biochemical Relapse-Free Survival Between High Dose Rate Brachytherapy and Open Radical Prostatectomy
    The Authors Journal Compilation, 2010 BJU International. 105 Supplement 1. 1-38. Abstract.
    Savdie R, Yuen C, Haynes A, DeBenito R, Rasiah K, Jagavka R, P Stricker P
  68. Robot-assisted Laparoscopic Prostatectomy: Analysis of an Experienced Open Surgeon's Learning Curve After 300 Procedures
    Journal of Robotic Surgery. (2010) 3;229-234
    N Dourmerc, Yuen C, P Stricker.
  69. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development
    Cancer Epidemiol Biomarkers Prev 19: 2611-2622
    Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O ’Loughlin M, Ryan NK, Raymond WA, Horvath LG Kench JG, Stricker P, Marshall VR, Sutherland R L, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Horsfall DJ, Tilley WD and Ricciardelli C (2010).
  70. Gene based predication of clinically localised prostate cancer progression after radical prostatectomy
    J Urology 184: 1521-1528.
    Talentov D, Jatkoe TA, Boehm M, Zhang Y, Ferguson AM, Stricker P, Kattan MW, Sutherland R L, Kench JG, Wang Y, and Henshall SM (2010).
  71. Advances in the management of benign prostatic hyperplasia
    Medicine Today. September 2011, Volume 12 Number 9
    Yuen C, Stricker P
  72. Low AZGP1 expression predicts for recurrence in margin positive, localised prostate cancer
    Prostate. 2011 Nov;71(15):1638-45
    Yip PY, Kench JG, Pebenito RP, Lee CS, Stricker P, Henshall SM, Sutherland R L and Horvath LG
  73. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy
    BJU Int. 2011 Oct 12
    Savdie R1, Horvath LG, Benito RP, Rasiah KK, Haynes AM, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL, Kench JG
  74. The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy
    BJU Int. 2012 Feb; 109(4): 533-8
    Moore BM, Savdie R, Pebenito RA, Haynes AM, Matthews J, Delprado W, Rasiah KK, Stricker P
  75. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer
    British Journal of Cancer (2012)106, 638-645
    King MT, Viney R, Smith DP,Hossain I, Street D, Savage E, Fowler S, Berry MP, Stockler M, Cozzi P, Stricker P, Ward J, Armb BK
  76. Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy
    J Urol.2012 188:781-785
    Hossack T, Patel MI, Huo A, Brenner P, Yuen C, Spernat D, Mathews J, Haynes A-M, Sutherland R L and Stricker P
  77. Accuracy of primary systematic template-guided transperineal biopsy of the prostate for locating prostate cancer: A comparison with radical prostatectomy specimens
    J Urol. 2012 April
    Huo AS, Hossack T, Symons JL, Pebenito R, Delprado WJ, Brenner P, Stricker P
  78. Survival in men diagnosed with prostate cancer: 8 to 10 year outcomes from the NSW Prostate Cancer Care and Outcomes Study
    Draft Abstract for Sydney Cancer Conference 2012
    David P Smith, Dianne O ’Connell, Albert Bang, Madeleine King, Martin Berry, Stricker P, Paul Cozzi, Armstrong B K
  79. A novel method of bladder neck imbrication to improve early urinary continence following robot-assisted ra dic al prostatectomy
    J Robotic Surg 2013 Jun;7(2):193-9
    Beattie K, Symons J, Chopra S, Yuen C, Savdie R, Thanigasalam R, Haynes A, Matthews J, Brenner PC, Rasiah K, Sutherland R L, Stricker P
  80. Impact of percentage of positive biopsy cores on biochemical outcome in patients treated with low-dose rate (Iodine-125) brachytherapy for prostate cance r
    Open Prostate Cancer Journal, 2012, 5: 15-19
    Yuen C, Hoassack T, Haynes A-M, Pe Benito RA, Matthews J, Fogarty G Jagavkar R, Brenner P and Stricker P
  81. Outcomes of transperineal template-guided prostate biopsy in 409 patients
    BJU 2013 Sep;112(5):585-93
    Symons JL, Huo A, Yuen CL Haynes A, Matthews J, Sutherland R L, Brenner P and Stricker P
  82. Informed prostate cancer risk- adjusted testing: a new paradigm
    BJU Int. 2012 Dec;110 Suppl 4:30-4
    Stricker P, Frydenberg M, Kneebone A, Chopra S
  83. Circulating microRNAs predict biochemical recurrence in prostate cancer patients
    BJC 2013 Aug 6;109(3):641-50
    Luke Selth, Scott Townley, Andrew Bert, Stricker P, Peter Sutherland, Horvath L, Gregory Goodall, Lisa Butler and Wayne Tilley.
  84. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer
    BJU Int. 2013 Nov;112 Suppl 2:6-20
    Thompson J, Lawrentschuk N, Frydenberg M, Thompson L and Stricker P on behalf of USANZ
  85. Magnetic resonance imaging detects significant prostate cancer and could be used to reduce unnecessary biopsies: initial results from a prospective trial
    J Urol 2013; May 8 Vol 189, Suppl 4S
    Thompson J, Stricker P, Brenner P, Moses D, Shnier R, Delprado W, Haynes, A-M, Hayen A.
  86. A multinational, multi-institutional study comparing positive surgical margin rates among 22,393 open, laparoscopic, and robot-assisted radical prostatectomy patients
    Eur Urol 24 Nov 2013
    Sooriakumaran P, Srivastava A, Shariat S, Stricker P, Ahlering T, Eden C, Wiklund P, Sanchez-Salas R, Mottrie A, Lee D, Neal D, Ghavamian, Nyirady P, Nilsson A, Carlsson, Xylinas E, Loidl W, Seitz C, Schramek P, Roehrborn C, Cathelineau X, Skarecky D, Shaw G, Warren A, Delprado W, Haynes AM, Steyerberg E, Roobol M and Tewari A
  87. Evaluation de la qualite de vie suite aux traitements actuels du cancer de prostate localiz e
    Progrès en Urologie Volume 23, Issue 13, November 2013, Page 1100
    Thanigasalama R, Baumert H, Stricker P, Brenner P, Egger S, Chopra S, Symons J, Savdie R, Haynes A, Bohme M, Elhajja A, Smith D, Sutherland R, Rasiah K
  88. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases
    Eur Urol. 2014 Mar;65(3):521-31
    Thompson J, Egger S, Bohn M, Haynes A-M, Matthews J, Rasiah K, Stricker P
  89. Medium-term oncologic outcomes for extended versus saturation biopsy and transrectal versus transperineal biopsy in active surveillance for prostate cancer
    BJU International 2014 DOI:10.1111/bju.12858
    Thompson J, Hayden A, Landau A, Haynes AM, Kalapara A, Ischia J, Matthews J, Frydenberg M and Stricker P.
  90. Extrapostatic extension of prostatic carcinoma: Is its proximity to surgical margin or Gleason score important?
    BJU International 2014 DOI: 10.1111/bju.12911
    Gupta R, O ’Connell R, Haynes A, Stricker P, Barrett W, Turner J J, Delprado W, Horvath L G and Kench J G
  91. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: A prospective study
    J Urology 2014; July 192: 67-74
    Thompson J, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Bohm M, Haynes A, Hayden A and Stricker P
  92. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer
    Prostate Cancer and Prostatic Diseases 2014, 1-5
    Valerio M, Stricker P, Ahmed HU, Dickinson L, Ponsky L, Shnier R, Allen C, Emberton M
  93. Expression of E6AP and PML predicts for prostate cancer progression and cancer specific death
    Annals of Oncology Sept 2014
    Birch SE, Kench JG , Takano E , Chan P , Chan AL , Chiam K , Veillard A-S , Stricker P , Haupt S , Haupt Y , Horvath L and Fox S B
  94. An update on the medical management of benign prostatic hypertrophy
    Medicine Today 2014; 15(10): 72-76
    Tran M, Stricker P
  95. An update on the medical management of prostate cancer
    Medicine Today 2015; 16(1): 42-48
    Tran M, Stricker P
  96. Combination of multi-parametric magnetic resonance imaging and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy
    BJU International February 2015
    Tran M, Thompson J, Savdie R, Moses M, Schnier R, Brenner P, Delprado W, Boehm M, Haynes AM, Pulbrook M and Stricker P
  97. Adverse effects of androgen-deprivation therapy in prostate cancer and their management
    BJU International April 2015: 115 (S5), 3-13
    Rhee H, Gunter J H, Heathcote P, Ho K, Stricker P, Corcoran NM, Nelson CC
  98. P rospective Comparison of the detection rate of 18F-Fluoromethylcholine and 68Ga-PSMA-HBED PET/CT in men with prostate cancer with rising PSA post curative treatment, being considered for targeted therapy
    J Nucl Med. 2015 Aug;56(8):1185-90
    Morigi J J, Stricker S, van Leeuwen P, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L and Louise Emmett L
  99. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control
    Prostate Cancer and Prostatic Disease (2016) 19, 46–52
    Ting F, Tran M, Bohm M, Siriwardana A, Van Leeuwen P, Haynes A, Delprado W, Shnier R, and Stricker P
  100. Tumour Volume in Insignificant Prostate Cancer: Increasing the threshold is a safe approach to reduce overtreatment
    Prostate. 2015 Nov;75(15):1768-73
    Ting F, van Leeuwen PJ, Delprado W, Haynes AM, Brenner P, Stricker P
  101. Volumetric Modulated Arc Therapy of the Pelvic Lymph Nodes to the aortic bifurcation in higher risk Prostate Cancer : Early Toxicity Outcomes
    Biomed Res Int 2015; 2015:696439. DOI: 10.1155/2015/696439. Epub 2015 Oct 11
    Hesselberg G , Fogarty G , Haydu L , Dougheney N , Stricker P
  102. Transperineal Prostate Biopsy
    Hinman ’s Atlas of Urologic Surgery, 4th edition. In Prostate: Malignancy pp. 552
    Symons J, Stricker P
  103. 68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment
    2016 May;117(5):732-9
    van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L
  104. The Diagnostic Performance of Multiparametric Magnetic Resonance Imaging to Detect Significant Prostate Cancer
    2016 May;195(5):1428-35
    Thompson JE , van Leeuwen PJ , Moses D , Shnier R , Brenner P , Delprado W , Pulbrook M , Bohm M , Haynes A, Hayen A, Stricker P
  105. Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional stud y
    J Magn Reson Imaging. 2017 Jul;46(1):184-193
    Ginsburg SB, Algohary A, Pahwa S, Gulani V, Ponsky L, Aronen HJ, Boström PJ, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Taimen P, Villani R, Stricker P, Rastinehad AR, Jambor I, Madabhushi A
  106. Editorial Comment
    J Urol. March 2017Volume 197, Issue 3, Part 1, Pages 653–654
    van den Bos W, Stricker P
  107. Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer
    2016 Dec;76(16):1491-1500
    Bruce HM, Stricker P, Gupta R, Savdie RR, Haynes AM, Mahon KL, Lin HM, Kench JG, Horvath LG
  108. Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer
    Aging (Albany NY). 2016 Oct 5;8(11):2702-2712
    Kalsbeek AM, Chan EF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM
  109. AutoStitcher: An Automated Program for Efficient and Robust Reconstruction of Digitized Whole Histological Sections from Tissue Fragments
    Sci Rep. 2016 Jul 26;6:29906
    Penzias G, Janowczyk A, Singanamalli A, Rusu M, Shih N, Feldman M, Stricker P, Delprado W, Tiwari S, Böhm M, Haynes AM, Ponsky L, Viswanath S, Madabhushi A
  110. Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy
    Prostate Cancer. 2016;2016:3794738
    Ting F, Van Leeuwen PJ, Thompson J, Shnier R, Moses D, Delprado W, Stricker P
  111. The role of MRI in prostate cancer: A changing paradigm.
    Medicine Today 2017; 18(1): 44-46
    Siriwardana A, van Den Bos W, Thompson J, Shnier R, Stricker PD
  112. A Multiparametric Magnetic Resonance Imaging Based Risk Model to Determine the Risk of Significant Prostate Cancer prior to biopsy
    BJU Int. 2017 Dec;120(6):774-781.
    Pim J. van Leeuwen, Andrew Hayen, James E. Thompson, Daniel Moses, Ron Shnier, Maret Böhm, Magdaline Abuodha, Anne‐Maree Haynes, Francis Ting, Jelle Barentsz, Monique Roobol, Justin Vass, Krishan Rasiah, Warick Delprado, Phillip D Stricker
  113. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer
    BJU Int. 2017 Feb;119(2):209-215
    van Leeuwen PJ, Emmett L, Ho B, Delprado W, Ting F, Nguyen Q, Stricker P
  114. Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies
    Prostate Cancer. 2016;2016:7105678
    van Leeuwen PJ, Siriwardana A, Roobol M, Ting F, Nieboer D, Thompson J, Delprado W, Haynes A, Brenner P, Stricker P
  115. Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide
    J Vasc Interv Radiol. 2016 Apr;27(4):568
    Ting F, Van Leeuwen PJ, Stricker P
  116. Enhancing active surveillance of prostate cancer: the potential of exercise medicine
    Nature Reviews Urology, 13, 258–265 2016
    Galvão DA, Taaffe DR, Spry N, Gardiner RA, Taylor R, Risbridger GP, Frydenberg M, Hill M, Chambers SK, Stricker P, Shannon T, Hayne D, Zopf E, Newton RU
  117. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment
    BJU Int. 2016 May;117(5):732-9
    van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L
  118. Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy
    BJU Int. 2016 Jan;117(1):48-54
    Tran M, Thompson J, Böhm M, Pulbrook M, Moses D, Shnier R, Brenner P, Delprado W, Haynes AM, Savdie R, Stricker P
  119. Personalising prostate cancer care. Part 1. Advances in diagnosis
    Medicine Today 2017; 18(2): 29-32
    Thompson J, Wardana S, Stricker P
  120. Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up
    BJU Int. 2017 Nov;120(5):651-658
    Grogan J, Gupta R, Mahon KL, Stricker PD, Haynes AM, Delprado W, Turner J, Horvath LG, Kench JG
  121. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.
    Ann Oncol. 2017 Aug 1;28(8):1903-1909
    Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, Boulas J, Vasilaris A, Henshall SM, Stricker PD, Kench JG and Horvath LG
  122. Initial multicentre experience of 68Gallium-PSMA PET/CT guided robot-assisted salavage lymphadectomy: acceptable safety profile but oncological benefit appears limited.
    BJU Int. 2017 Nov;120(5):673-681
    Siriwardana A, Thompson J, van Leeuween P, Doig S, Kalsbeek A, Emmett L, Deprado W, Wong D, Samaratunga H, Haynes A, Coughlin G, Stricker P
  123. The implact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study
    J Nucl Med. 2017 Jun 23
    Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen Q, Thompson B, Cusick T, McCarthy M, Tang C, Ho B, Stricker P and Scott A
  124. Imaging: MRI improves cost and accuracy of prostate cancer biopsy
    Nat Rev Urol. 2018 Jan;15(1):6-8
    James Thompson, Phillip Stricker
  125. Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation
    Eur Urol Focus. 2017 Nov 1. pii: S2405-4569(17)30244-4. doi: 10.1016/j.euf.2017.10.007. [Epub ahead of print]
    Scheltema MJ, Chang JI, van den Bos W, Böhm M, Delprado W, Gielchinsky I, de Reijke TM, de la Rosette JJ, Siriwardana AR, Shnier R, Stricker PD
  126. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer
    BJU Int. 2017 Nov;120 Suppl 3:51-58. doi: 10.1111/bju.13991. Epub 2017 Sep 19
     Scheltema MJ, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Böhm M, Haynes AM, Shnier R, Delprado W, Stricker PD
  127. Focal irreversible electroporation as primary treatment for localized prostate cancer
    BJU Int, 121: 716-24.
    van den Bos,W., Scheltema, M. J., Siriwardana, A. R., Kalsbeek A. M. F., Thompson, J. E., Ting, F., Böhm, M., Haynes, A. M., Shnier, R., Delprado, W., Stricker, P. D.
  128.  Treatment outcomes from 68 GaPSMA PET CT informed salvage radiation treatment in men with rising PSA following radical prostatectomy: Prognostic value of a negative PSMA PET
    J Nucl Med. 2017 Dec;58(12):1972-1976.
    Louise Emmett1, Pim J. van Leeuwen, Rohan Nandurkar, Matthijs J. Scheltema, Thomas Cusick, George Hruby, Andrew Kneebone, Thomas Eade, Gerald Fogarty, Raj Jagavkar, Quoc Nguyen, Bao Ho, Anthony M. Joshua and Phillip Stricker
  129. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter stud
     Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen Q, Thompson B, Cusick T, McCarthy M, Tang C, Ho B, Stricker P, Scott A
    J Nucl Med. 2017 Jun 23. pii: jnumed.117.197160. doi: 10.2967/jnumed.117.197160. [Epub ahead of print]
  130. Computational imaging reveals shape differences between normal and malignant prostates on MRI
    Sci Rep. 2017 Feb 1;7:41261. doi: 10.1038/srep41261
    Rusu M, Purysko AS, Verma S, Kiechle J, Gollamudi J, Ghose S, Herrmann K, Gulani V, Paspulati R, Ponsky L, Böhm M, Haynes AM, Moses D, Shnier R, Delprado W, Thompson J, Stricker P, Madabhushi A
  131. Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer
    Lancet. 2017 Feb 25;389(10071):767-768. doi: 10.1016/S0140-6736(17)30121-6. Epub 2017 Jan 23. No abstract available
    Thompson JE, Stricker PD
  132. Decision-Making in Prostate Cancer: Active Surveillance Over Other Treatment Options
     Urol Nurs. 2016 May-Jun;36(3):141-9
    Bayliss D, Duff J, Stricker P, Walker K
  133. Personalising prostate cancer care. Part 2. Advances in treatment
    Medicine Today 2017; 18(3): 28-33
    Siriwardana A, Thompson J, Stricker P
  134. Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.
    Prostate. 2018 Jan;78(1):25-31
    Anton M. F. Kalsbeek, Eva K. F. Chan, Judith Grogan, Desiree C. Petersen, Weerachai Jaratlerdsiri, Ruta Gupta, Ruth J. Lyons, Anne‐Maree Haynes, Lisa G. Horvath, James G. Kench, Phillip D. Stricker, Vanessa M. Hayes
  135. Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings.
    J Magn Reson Imaging. 2018 Feb 22
    Algohary A, Viswanath S, Shiradkar R, Ghose S, Pahwa S, Moses D, Jambor I, Shnier R, Böhm M, Haynes AM, Brenner P, Delprado W, Thompson J, Pulbrock M, Purysko AS, Verma S, Ponsky L, Stricker P, Madabhushi A.
  136. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy
    World J Urol. 2018 Mar 28.
    Matthijs J. Scheltema, John I. Chang, Maret Böhm, Willemien van den Bos, Alexandar Blazevsk, Ilan Gielchinsky, Anton M. F. Kalsbeek, Pim J. van Leeuwen, Tuan V. Nguyen, Theo M. de Reijke, Amila R. Siriwardana, James E. Thompson, Jean J. de la Rosette, Phillip D. Stricker
  137. Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten
    Epigenetics Chromatin. 2018 May 28;11(1):24
    Shalima S. Nair, Phuc-Loi Luu†, Wenjia Qu, Madhavi Maddugoda, Lily Huschtscha, Roger Reddel, Georgia Chenevix-Trench, Martina Toso, James G. Kench, Lisa G. Horvath, Vanessa M. Hayes, Phillip D. Stricker, Timothy P. Hughes, Deborah L. White, John E. J. Rasko, Justin J.-L. Wong and Susan J. Clark
  138. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer
    Prostate. 2018 Mar;78(4):308-317
    Hui‐Ming Lin, Brian Y. Lee, Lesley Castillo, Calan Spielman, Judith Grogan, Nicole K. Yeung James G. Kench, Phillip D. Stricker, Anne‐Maree Haynes, Margaret M. Centenera, Lisa M. Butler S. Martin Shreeve, Lisa G. Horvath, Roger J. Daly
  139. P53 as a predictor of clinical outcome in localized prostate cancer.
    Journal of Clinical Oncology 36(6_suppl):57-57 · February 2018
    Kate Lynette Mahon, Phillip Stricker, James Kench, Judith Grogan, Warick Delprado, Jenny Turner, Lisa Horvath, David I. Quinn
  140. Staging with Ga-68 HBED-CC-Glu-NH-CO-NH-Lys (Ahx) PSMA-11 PET CT (PSMA) prior to radical prostatectomy has high predictive value in assessing biochemical response to surgery
    Eur Urol Suppl 2018; 17(2);e1903
    L. Emmett, R. Nandurkar, P. Van Leeuwen, H. Woo, R. Kooner, D. Ende, G. O’Neill, C. Yuen, B. Ho, Q. Nguyen, A. Hickey, P. Stricker
  141. MRI in active surveillance: adds value but positive and negative predictive value are inadequate to replace biopsy altogether.
    Accepted Editorial BJUI May 2018
    James E Thompson & Phillip D Stricker
  142. An analysis of multiple biomarkers to better predict prostate cancer metastasis and death after radical prostatectomy.
    Journal of Clinical Oncology 36(6_suppl):54-54 February 2018
    Alison Yan Zhang, Karen Chiam, Ygal Haupt, Stephen B. Fox, Simone Birch, Wayne Tilley, Lisa Butler, Karen E. Knudsen, Christopher Cornstock, Krishan Rasiah, Judith Grogan, Kate Lynette Mahon, Tina Bianco-Miotto, Maret Bohm, Susan M. Henshall, Warick Delprado, Phillip Stricker, Lisa Horvath, James Kench
  143. Enduring epigenetic landmarks define the cancer microenvironment
    Genome Res. 2018 May;28(5):625-638
    Ruth Pidsley, Mitchell G. Lawrence, Elena Zotenko, Birunthi Niranjan, Aaron Statham, Jenny Song, Roman M. Chabanon, Wenjia Qu, Hong Wang, Michelle Richards, Shalima S. Nair, Nicola J. Armstrong, Hieu T. Nim, Melissa Papargiris, Preetika Balanathan, Hugh French, Timothy Peters, Sam Norden, Andrew Ryan, John Pedersen, James Kench, Roger J. Daly, Lisa G. Horvath, Phillip Stricker, Mark Frydenberg, Renea A. Taylor, Clare Stirzaker, Gail P. Risbridger, and Susan J. Clark
  144. Genito-Urinary Function & QOL after Focal IRE of different Prostate Segments
    Accepted Diagnostic & Interventional Radiology 2018
    Scheltema M ... Stricker PD
  145. Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve—Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases
    Eur Urol. 2018 May;73(5):664-671.
    James E. Thompson'Correspondence information about the author James E. ThompsonEmail the author James E. Thompson, Sam Egger, Maret Böhm, Amila R. Siriwardana, Anne-Maree Haynes, Jayne Matthews, Matthijs J. Scheltema, Phillip D. Stricker
  146. Whole Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naive High-Risk Prostate Cancer.
    Cancer Res, Published Online September 14, 2018.
    Jaratlerdsiri, W., Chan, E. K. F., Gong, T., Petersen, D. C., Kalsbeek, A. M. F., Venter, P. A., Stricker, P. D., Bornman, M. S. R., Hayes, V. M.
  147. Prostate Cancer in 432 men under the age of 50 years in the Prostate Specific Antigen era - a new outlook.
    BJU International. Published online 10 October, 2018.
    Gielchinsky, I, Chang, J, Cusick, T, Delprado, W, Nguyen, Q, Yuen, C, Savdie, R, Böhm, M, Haynes, AM, Scheltema, M, and Stricker, P
  148. Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50.
    Research and reports in urology, 10, 145-150.
    Gielchinsky, I., Scheltema, M. J., Cusick, T., Chang, J., Shnier, R., Moses, D., Delprado, W., Nguyen, Q., Yuen, C., Haynes, A. M., and Stricker, P. D
  149. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments
    Diagn Interv Radiol, 24: 268-75.
    Scheltema, M. J., J. I. Chang, W. van den Bos, I. Gielchinsky, T. V. Nguyen, T. M. Reijke, A. R. Siriwardana, M. Bohm, J. J. de la Rosette, and P. D. Stricker
  150. Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings
    PLoS One, 13: e0200730.
    Penzias, G., A. Singanamalli, R. Elliott, J. Gollamudi, N. Shih, M. Feldman, P. D. Stricker, W. Delprado, S. Tiwari, M. Bohm, A. M. Haynes, L. Ponsky, P. Fu, P. Tiwari, S. Viswanath, and A. Madabhushi
  151. MRI improves active surveillance of prostate cancer however biopsy is still crucial
    BJU Int, 122: E1-E2.
    Thompson, J. E., and P. D. Stricker
  152. 68Ga PSMA PET/CT predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate and high-risk prostate cancer.
    BJU Int.
    van Leeuwen, P. J., Donswijk, M., Nandurkar, R., Stricker, P., Ho, B., Heijmink, S., Wit, E. M. K., Tillier, C., van Muilenkom, E., Nguyen, Q., van der Poel, H. G. & Emmett, L. (2018)
  153. (68)Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery.
    Br J Radiol 92(1095): 20180667.
     Nandurkar, R., van Leeuwen, P., Stricker, P., Woo, H., Kooner, R., Yuen, C., O'Neill, G., Ende, D., Cusick, T., Ho, B., Hickey A. & Emmett, L.
  154. Results of a Prospective Phase 2 Pilot Trial of (177)Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression.
    Clin Genitourin Cancer 17(1): 15-22.
    Emmett, L., Crumbaker, M., Ho, B., Willowson, K., Eu, P., Ratnayake, L., Epstein, R., Blanksby, A., Horvath, L., Guminski, A., Mahon, K., Gedye, C., Yin, C., Stricker, P. & Joshua, A. M. (2019)
  155. Early outcomes after [68Ga]PSMA-PET/CT guided salvage therapy in men with biochemical recurrence after radical prostatectomy
    (Vroege oncologische uitkomsten van [68Ga]PSMA-PET/CT-gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie)
    Tijdschrift voor Urologie 9(1): 2-8.
    van Leeuwen, P. J., Emmett, l., Donswijk, M. L., Stricker, P. D., Pos, F. J., Wit, E. M. K. & van der Poel, H. G. (2019).
  156. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
    BJU Int 123(2): 284-292.
    Bancroft, E. K., Saya, S., Page, E. C., Myhill, K., Thomas, S., Pope, J., Chamberlain, A., Hart, R., Glover, W., Cook, J., Rosario, D. J., Helfand, B. T., Hutten, C. S., Davidson, R., Longmuir, M., Eccles, D. M., Gadea, N., Brewer, C., Barwell, J. , Salinas, M., Greenhalgh, L., Tischkowitz, M., Henderson, A., Evans, D. G., Buys, S. S., Eeles, R. A., IMPACT Collaborators* and Aaronson, N. K. (2019).
  157. Imaging: MRI improves cost and accuracy of prostate cancer biopsy.
    Nat Rev Urol, 15(1), 6-8.
     Thompson, J., & Stricker, P. (2018)
back to top

Key aspects

From diagnosis and treatment to rehabilitation and research, I believe my highly experienced team and I bring a multifaceted approach to understanding and helping our patients. A summary of these key aspects of that approach is available here in PDF format. If you are suffering from prostate cancer or have reason to believe you might be, you are welcome to contact us or, intially, complete our comprehensive second opinion form.

AMA
FRACS
USANZ